Acer therapeutics announces olpruva™ commercial launch progressing ahead of schedule

Availability: olpruva™ drug in channel now anticipated in mid-june 2023 awareness: 70% of metabolic treatment providers surveyed by acer at simd annual meeting indicated an interest in treating at least one of their patients with olpruva™ in 2023 reimbursement: acer engaged in discussions with payers representing a substantial majority of covered lives newton, mass., may 01, 2023 (globe newswire) -- acer therapeutics inc. (nasdaq: acer ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced an update on progress in support of its commercial launch of olpruva™ (sodium phenylbutyrate) for oral suspension, including drug availability now expected earlier than anticipated in mid-june 2023, subject to additional capital.
ACER Ratings Summary
ACER Quant Ranking